Projected Price to Earnings: Haleon PLC (HLN)

Graphic logo of Haleon Corp (HLN)

A broad portfolio of well-known brands allows Haleon plc (HLN) to effectively index product pricing and maintain margins. Stable demand for hygiene products ensures crisis resilience, which is supported by the business's forward P/E multiple. The current 15.50 captures the market valuation, while strong human capital and specialist loyalty guarantee the company's qualitative development.

HLN - haleon.com Future Price to Earnings Multiple over the range 04/28/2023 - 11/16/2026

Financial and market metric breakdowns for Haleon plc (HLN)

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Fundamental valuation:Haleon PLC
Signature product of Haleon Corp

The long-term reliability of Haleon plc is determined by the business's ability to convert future earnings into actual cash flow. The forward P/E ratio relates the current share price to expected earnings, revealing whether the asset is overvalued or undervalued. The trend of the company's forward price-to-earnings ratio visualizes the balance between market expectations and solvency. A decline in this metric may signal debt risks. The stability of this indicator is supported by optimized over-the-counter drug logistics, which minimize distribution costs.

Analysis of competing companies

Projected Price to Earnings KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Jyong Biotech Limited MENS|Ligand (LGND) - Projected Price to Earnings Ratio|AMRX: Projected Price to Earnings|Perrigo - Market Cap to Future Earnings Ratio|ALVO: Forward P/E Multiple|Liquidia Technologies - Future Price to Earnings Multiple|GLPG (Galapagos N.V.) - Forward P/E Multiple|Projected Price to Earnings Ratio anipharmaceuticals.com ANIP|Future Price to Earnings MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|Forward P/E Multiple ARS Corp SPRY|Theravance Biopharma - Forward P/E Multiple|Forward Price to Earnings Multiple Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Future Price to Earnings|Projected Price to Earnings Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forward P/E Multiple|Price to Future Earnings Ratio SXTC (China SXT Pharmaceuticals)|Forward P/E Multiple EPRX|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP